Welcome to the e-CCO Library!

P639 Outcomes of a clinical psychology intervention in a UK IBD service
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Eldridge DClin Psyc, K. Strongili, M. Parkes, T. Raine

Created: Thursday, 30 January 2020, 10:12 AM
P639: Epidemiology and patient burden of rectovaginal and anovaginal fistulas in patients with Crohn’s disease: A systematic review
Year: 2021
Source: ECCO'21 Virtual
Authors: Iglay, K.(1);Bennett, D.(2,3);Kappelman, M.(4);Thai, S.(1,5);Aldridge, M.(1);Karki, C.(2);Cook, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P639: Incidence and disease presentation of inflammatory bowel disease in Denmark: initial findings from a Copenhagen IBD Inception Cohort Study
Year: 2022
Source: ECCO'22
Authors: Dorn-Rasmussen, M.(1);Attauabi, M.(2);Madsen, G.R.(3);Wewer, A.V.(1);Jansson, S.(1);Knudsen, M.M.(1);Wilkens, R.(3);Ilvemark, J.F.K.F.(2);Bjerrum, J.W.(2);Theede, K.(3);Bendtsen, F.(3);Trine, B.(3);Seidelin, J.B.(2);Burisch, J.M.(3);
Created: Friday, 11 February 2022, 3:56 PM
P639: Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Theodoraki*1, E. Orfanoudaki1, K. Foteinogiannopoulou1, E. Legaki2, M. Gazouli2, I. Koutroubakis1

Created: Friday, 22 February 2019, 9:41 AM
P639: Percutaneous drainage vs surgery as definitive treatment for anastomotic leak after intestinal resection in patients with Crohn's disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Belvedere, A.(1)*;Dajti, G.(1);Larotonda, C.(1);Angelicchio, L.(1);Rizzello, F.(2);Gionchetti, P.(2);Poggioli, G.(1);Rottoli, M.(1);
Created: Friday, 14 July 2023, 11:12 AM
P639: Switching from originator-infliximab to biosimilar-Infliximab in IBD-patients does not lead to significant changes in infliximab trough levels
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Eberl A.*1,2, Huoponen S.2, Pahikkala T.3, Arkkila P.1,2, Blom M.2, Sipponen T.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P639: Validation of the Quantum Blue® infliximab-level rapid test in clinical practice of patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Strik1*, T. Schuster2, M. Löwenberg1, C. Ponsioen1, G. D'Haens1

Created: Thursday, 21 February 2019, 9:14 AM
P640 Moderate to severe endoscopic inflammation is frequent after clinical remission in pediatric ulcerative colitis: A cause for disease extension and relapse?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Sarbagili Shabat1,2, D. Weiner1, J. Wardi3, L. Abramas1, M. Yaakov1, A. Levine1,2

Created: Thursday, 30 January 2020, 10:12 AM
P640: Characteristics of elderly onset Inflammatory Bowel Disease in a cohort of Hispanics
Year: 2021
Source: ECCO'21 Virtual
Authors: Ramos, L.(1);Anca, M.(1);Feliciano, K.(1);Amaya, C.(2);Perez, A.(3);Torres, E.A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P640: Evaluation of dietetic services and the impact of diet on disease activity for patients with inflammatory bowel disease at Imperial College Healthcare NHS Trust
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Sandhar*1, N. Direkze2, S. Peake2

Created: Friday, 22 February 2019, 9:41 AM
P640: Incidence, prevalence, disease phenotype and maximal therapeutic step in Crohn’s disease patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem county cohort
Year: 2022
Source: ECCO'22
Authors: Lakatos, L.(1);Gonczi, L.(2);Golovics, P.(3);Pandur, T.(4);David, G.(1);Erdelyi, Z.(1);Szita, I.(1);LakatosPhD, P.L.(2,5);
Created: Friday, 11 February 2022, 3:56 PM
P640: Risk of post-operative complications among Crohn’s disease patients treated pre-operatively with vedolizumab. A matched case–control study
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.Y. Kim1, K. Zaghiyan2, P. Fleshner2*

Created: Thursday, 21 February 2019, 9:14 AM
P640: Serologic response and safety after third dose of the COVID-19 BNT162b2 vaccine in patients with Inflammatory Bowel Diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Edelman-Klapper, H.(1,2)*;Rabinowitz, K.M.(1,3); Zittan, E.(4,5);Bar-Gil Shitrit, A.(6,7);Goren, I.(1,2);Avni-Biron, I.(1,2);Ollech, J.E.(1,2);Lichtenstein, L.(8);Banai-Eran, H.(1,2);Yanai, H.(1,2);Snir, Y.(1,2);Pauker, M.H.(1,2);Friedenberg, A.(1);Levy-Barda, A.(9);Segal, A.(10);Broitman, Y.(1,2);Maoz, E.(11);Ovadia, B.(12);Aharoni Golan, M.(1,2);Shachar, E.(2,13);Ben-Horin, S.(2,13);Mor, M.(11);Ben Zvi, H.(2,14);Perets, T.T.(15,16);Eliakim, R.(2,13);Barkan, R.(1);Navon, M.(17);Gal-Tanamy, M.(18);Freund, N.T.(17);Goren, S.(19);Cohen, D.(19);Dotan, I.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P640: Serum ustekinumab levels achieved with a subcutaneous induction regimen correlate to clinical outcome – a prospective study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rowan C.R.*1, Kalei A.2, De Vries A.2, Cullen G.3,4, Ryan E.1,4, Mulcahy H.3,4, D'Haens G.5, Doherty G.A.3,4

Created: Wednesday, 20 February 2019, 10:36 AM
P641 An increased baseline mucosal TNF burden linked to adalimumab non-response: opportunities for therapeutic drug monitoring
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Verstockt1, J. Stylli2, P. Rahimian2, A. Rajulapati2, K. Ehring2, D. Thomas3, J. Sabino1, M. Ferrante1, S. Singh2, S. Vermeire1

Created: Thursday, 30 January 2020, 10:12 AM
P641: Bowel Doppler Signal, the most important ultrasonographic feature in clinical practice in managing Inflammatory Bowel Diseases patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Les, A.(1)*;Cotruta, B.(1);Iacob , R.(1,2);Saizu, R.(1,2);Gheorghe, L.(1,2);Gheorghe, C.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P641: Comparison of rectal and oral mesalazine for treatment of rectal ulcerative proctitis: A prospective randomised clinical trial (CORRECT study)
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Kato1*, K. Kani1, H. Kurihara2, T. Ohmori3, K. Yakabi1

Created: Thursday, 21 February 2019, 9:14 AM
P641: Impact of lockdown period due to COVID-19 pandemic in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: García Mateo, S.(1,2);Refaie, E.(3);Martínez-Domínguez, S.J.(1,2);Gargallo-Puyuelo, C.J.(1,2,4);Lario Quilez, L.(1);Carrera-Lasfuentes, P.(5);Arroyo Villarino, M.T.(1,2,4);Aso Gonzalvo, M.C.(1);Gomollón García, F.(1,2,4,5);
Created: Wednesday, 2 June 2021, 4:12 PM
P641: Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey
Year: 2022
Source: ECCO'22
Authors: Revés, J.(1);Abreu, B.(1);Chaparro, M.(2);Gisbert, J.P.(2);Mariangela, A.(3);Fiorino, G.(3);Barberio, B.(4);Zingone, F.(4);Pisani, A.(5);Cassar, D.(5);Michalopoulos, G.(6);Mantzaris, G.(7);Mountaki, K.(7);Koutroubakis, I.(8);Karmiris, K.(9);Katsanos, K.(10);Ďuricova, D.(11);Burisch, J.(12);Madsen, G.R.(12);Maaser, C.(13);Naila, A.(14);Orfanoudaki, E.(8);Milivojevic, V.(15);Buisson, A.(16);Avedano, L.(17);Leone, S.(18);Torres, J.(1);Ellul, P.(5);
Created: Friday, 11 February 2022, 3:56 PM
P641: Long-term outcome of adalimumab therapy and predictors of response in 254 patients with Crohn's disease: a hospital-based cohort study from Korea
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Seo H.*1, Ye B.D.1,2, Lee S.-H.1, Chang K.1, Song E.M.1, Kim G.-U.1, Seo M.1, Lee H.-S.3, Hwang S.W.1,2, Park S.H.1,2, Yang D.-H.1, Kim K.-J.1,2, Byeon J.-S.1, Myung S.-J.1, Yang S.-K.1,2

Created: Wednesday, 20 February 2019, 10:36 AM